Insider information
January 22[nd], 2021 at
Nanoform's Clinical Study Indicates Positive Interim Results
Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the Pharmacokinetic (PK) Profile of Piroxicam following
This first set of human data supports Nanoform's value proposition that nanoparticles can enable faster dissolution rate, more rapid absorption, improve drug delivery performance, and ultimately generate patient benefit.
The interim results obtained from the ongoing clinical trial, suggest that a 20 mg nanoformed oral piroxicam tablet achieved significantly faster absorption when compared to a 20 mg reference oral piroxicam tablet (Felden[®]) from the originator
For further information, please contact:
Prof. Edward Hæggström, CEO
edward.haeggstrom@nanoform.com
+358 29 370 0150
For investor relations queries, please contact:
hvh@nanoform.com
+46 7686 650 11
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on January 22[nd], 2021 at
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on
https://news.cision.com/nanoform/r/nanoform-s-clinical-study-indicates-positive-interim-results,c3272304
https://mb.cision.com/Main/18905/3272304/1362243.pdf
(c) 2021 Cision. All rights reserved., source